Discover
BSG From Top to Bottom
BSG From Top to Bottom
Author: British Society of Gastroenterology
Subscribed: 17Played: 28Subscribe
Share
© 2025
Description
British Society of Gastroenterology's podcast, From Top to Bottom, gives you all the latest insights shaping modern gastroenterology practice from inspirational interviews to guideline summaries from leading experts.
Whether you're a gastroenterologist, trainee, or other healthcare professional seeking practical, evidence based updates — this podcast keeps you current from top to bottom.
Whether you're a gastroenterologist, trainee, or other healthcare professional seeking practical, evidence based updates — this podcast keeps you current from top to bottom.
19 Episodes
Reverse
Recorded at the BSG annual meeting in Liverpool, this episode features Professor Florian Rieder of the Cleveland Clinic, who joins the BSG IBD committee Chair and Co-chair, Dr Shahida Din and Dr Gareth Parkes, to discuss the arrival of the first randomised trials of anti-fibrotic therapies in Crohn’s disease.
Rieder, a founder of the STAR Consortium, explains how trials recruit through radiology rather than endoscopy, why stricture morphology is the endpoint of choice, and why fibrosis has lagged so far behind inflammation in drug development. The conversation also covers safety questions, whether strictures and fistulas are distinct phenotypes, practical design issues such as background therapy and placebo arms, and the potential for locally delivered drugs in IBD-associated PSC. Essential listening for anyone interested in where fibrosis research is heading.
Chapters
(00:00:00) - Introduction and Fibrosis Trial Landscape(00:01:16) - Imaging-Based Trial Design and Eligibility(00:02:59) - Incorporating Bowel Motility into Endpoints(00:04:16) - Why Fibrosis Therapies Have Lagged Behind(00:06:28) - Safety Concerns and Local Drug Delivery(00:07:48) - Strictures vs Fistulizing Disease Progression(00:10:41) - Balancing Anti-Fibrotic and Anti-Inflammatory Therapy(00:13:19) - Placebo Arms and Ethical Trial Design(00:15:51) - Potential Applications in PSC and Closing Remarks
Dr. Noor Jawad, consultant gastroenterologist and the new BSG mentoring lead, discusses the value of mentoring in healthcare careers with Dr Francesca Moroni, consultant at NHS Grampian, Aberdeen. They describes how the free BSG mentoring platform matches mentors and mentees, how the relationship can be structured around the mentee’s goals, and the benefits mentoring brings to mentors as well as mentees. They also addresses the importance of clear boundaries and signposting to specialist support, and makes the case for mentoring as a means of supporting and retaining the workforce.
To watch the interview, click here: https://www.bsg.org.uk/web-education/how-to-be-a-good-mentor
Chapters
(00:00:00) - Introduction and Importance of Mentoring(00:00:41) - What Makes a Good Mentor(00:02:12) - Reverse Mentoring and Inclusivity(00:03:02) - How the BSG Mentoring Platform Works(00:04:28) - Benefits for Mentors(00:05:19) - Setting Up the Mentor-Mentee Relationship(00:06:49) - Mentee-Driven Goals and Preparation(00:07:40) - Boundaries and Limits of Mentoring(00:09:17) - Raising Awareness and Closing Thoughts
Consultant gastroenterologists Dr Hugo Penny, Sheffield Teaching Hospitals NHS Foundation Trust and Dr. Michael Fitzpatrick, Oxford University Hospitals NHS Foundation Trust, discuss why new Coeliac Disease treatments are needed and what is on the horizon. They review the drug pipeline, which targets the known antigen and immune response: cytokine inhibitors (e.g. IL-15), gluten-degrading enzymes, tissue transglutaminase 2 (TG2) inhibitors, and tolerogenic therapies. JAK inhibitors show promise in refractory coeliac disease.With no licensed therapies and no regulatory roadmap, several agents are in phase 2 trials, with anti-TG2 therapy furthest advanced. Trials currently focus on adults with ongoing disease despite at least 12 months on a GFD, with paediatric patients a likely future focus.
To watch the interview, click here: https://www.bsg.org.uk/web-education/immunological-and-therapeutic-coeliac-disease
In this episode, Dr. Asma Fikree, Consultant Neurogastroenterologist at UCLH and Chair of the BSG Neurogastroenterology & Motility Section and Dr Maria Eugenicos, Senior Lecturer/Neurogastroenterologist, Western General Hospital, Edinburgh discuss the effects of anti-obesity medications on gastric motility, dyspepsia, and gastroparesis-like symptoms.
The discussion covers the management of nausea, vomiting and delayed gastric emptying, considerations before endoscopy and surgery, the phenomenon of tachyphylaxis, and practical approaches to dose titration. Dr. Fikree also examines the emerging evidence for GLP-1 therapies in patients with IBS and chronic gastrointestinal symptoms, highlighting both the benefits and limitations of these increasingly prescribed treatments.
Professor Vikram Mitra (Chair, Pancreas Clinical Section, British Society of Gastroenterology) speaks with Professor Pramod Garg, President of the Indian Society of Gastroenterology, about the link between gut microbiome and acute pancreatitis.
Topics include whether admission microbiome can predict disease severity, which bacterial classes (notably Proteobacteria) are tied to worse outcomes, and what's known about how gut bacteria may drive pancreatic inflammation. They also discuss the case against prophylactic antibiotics, why early enteral nutrition beats bowel rest, mixed results on interventions like rifaximin, and key confounders in microbiome research (diet, ethnicity, drug use, disease etiology).
To watch the interview, click here: https://www.bsg.org.uk/web-education/gut-microbiome-in-acute-pancreatitis








